Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 2384 results:
Author Title [ Type(Asc)] Year
Journal Article
A. Tran-Duy, Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., and de Boer, A., “Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study”, J Intern Med, 2018.
R. L. Tannen, Weiner, M. G., and Xie, D., “Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings”, Bmj, vol. 338, p. b81, 2009.
P. Tammes, Sartini, C., Preston, I., Hay, A. D., Lasserson, D., and Morris, R. W., “Use of primary care data to predict those most vulnerable to cold weather: a case-crossover analysis”, Br J Gen Pract, vol. 68, pp. e146-e156, 2018.
L. Azoulay, Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., and Suissa, S., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study”, Bmj, vol. 344, p. e3645, 2012.
A. Keyany, Nielen, J. T. H., Souverein, P. C., de Vries, F., and van den Bemt, B., “Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study”, Diabetes Res Clin Pract, vol. 139, pp. 100-106, 2018.
P. C. Souverein, Berard, A., van Staa, T. P., Cooper, C., Egberts, A. C., Leufkens, H. G., and Walker, B. R., “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
J. Gorricho, Garjon, J., Alonso, A., Celaya, M. C., Saiz, L. C., Erviti, J., and Lopez, A., “Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study”, Br J Clin Pharmacol, vol. 83, pp. 2034-2044, 2017.
R. G. Schlienger, Jick, H., and Meier, C. R., “Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction”, Br J Clin Pharmacol, vol. 54, pp. 327-32, 2002.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
S. J. Roberts and Bateman, D. N., “The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmacoepidemiological study”, Br J Clin Pharmacol, vol. 38, pp. 489-97, 1994.
J. Watson, Jones, H. E., Banks, J., Whiting, P., Salisbury, C., and Hamilton, W., “Use of multiple inflammatory marker tests in primary care: using Clinical Practice Research Datalink to evaluate accuracy”, Br J Gen Pract, vol. 69, pp. e462-e469, 2019.
M. Bodmer, Becker, C., Meier, C., Jick, S. S., and Meier, C. R., “Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis”, Cancer Epidemiol Biomarkers Prev, vol. 21, pp. 280-6, 2012.
M. Bodmer, Becker, C., Meier, C., Jick, S. S., and Meier, C. R., “Use of metformin and the risk of ovarian cancer: a case-control analysis”, Gynecol Oncol, vol. 123, pp. 200-4, 2011.
B. B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and the incidence of lung cancer in patients with type 2 diabetes”, Diabetes Care, vol. 36, pp. 124-9, 2013.
B. Smiechowski, Azoulay, L., Yin, H., Pollak, M. N., and Suissa, S., “The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus”, Cancer Epidemiol Biomarkers Prev, vol. 22, pp. 1877-83, 2013.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
L. M. Knapen, van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G., Croes, S., Neef, C., de Vries, F., and Driessen, J. H., “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
L. M. Knapen, de Jong, R. G., Driessen, J. H., Keulemans, Y. C., van Erp, N. P., De Bruin, M. L., Leufkens, H. G., Croes, S., and de Vries, F., “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 364, p. k4810, 2019.
J. Shawe, Mulnier, H., Nicholls, P., and Lawrenson, R., “Use of hormonal contraceptive methods by women with diabetes”, Prim Care Diabetes, vol. 2, pp. 195-9, 2008.
C. R. Dormuth, Hemmelgarn, B. R., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Lafrance, J. P., Levy, A., Garg, A. X., and Ernst, P., “Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases”, Bmj, vol. 346, p. f880, 2013.
M. Tuccori, Wu, J. W., Yin, H., Majdan, A., and Azoulay, L., “The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes”, Diabetes Care, vol. 38, pp. 2083-9, 2015.
S. Dial, Delaney, J. A., Barkun, A. N., and Suissa, S., “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease”, Jama, vol. 294, pp. 2989-95, 2005.
F. Andersohn, Suissa, S., and Garbe, E., “Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction”, Circulation, vol. 113, pp. 1950-7, 2006.
V. Mandilaras, Bouganim, N., Yin, H., Asselah, J., and Azoulay, L., “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
S. Bruderer, Bodmer, M., Jick, S. S., and Meier, C. R., “Use of diuretics and risk of incident gout: a population-based case-control study”, Arthritis Rheumatol, vol. 66, pp. 185-96, 2014.
W. R. der Zanden, de Vries, F., Lalmohamed, A., Driessen, J. H., de Boer, A., Rohde, G., Neef, C., and C. Heijer, den, “Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study”, PLoS One, vol. 10, p. e0139367, 2015.
J. H. Driessen, van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., Leufkens, H. G., and de Vries, F., “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
L. E. Derby, Myers, M. W., and Jick, H., “Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke”, Br J Clin Pharmacol, vol. 47, pp. 565-9, 1999.
L. L. Lanza, McQuay, L. J., Rothman, K. J., Bone, H. G., Kaunitz, A. M., Harel, Z., Ataher, Q., Ross, D., Arena, P. L., and Wolter, K. D., “Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture”, Obstet Gynecol, vol. 121, pp. 593-600, 2013.
C. Meier, Brauchli, Y. B., Jick, S. S., Kraenzlin, M. E., and Meier, C. R., “Use of depot medroxyprogesterone acetate and fracture risk”, J Clin Endocrinol Metab, vol. 95, pp. 4909-16, 2010.
D. M. Carbonari, Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., Wood, J., Gallagher, A. M., Bhullar, H., Cardillo, S., Hennessy, S., Strom, B. L., and , “Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 999-1003, 2015.
T. P. van Staa, Abenhaim, L., and Cooper, C., “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 350, p. h2135, 2015.
L. A. Garcia Rodriguez, Johansson, S., and L. Soriano, C., “Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding”, Thromb Haemost, vol. 110, pp. 1014-24, 2013.
A. Ruigomez, Rodriguez, L. A. Garcia, Cattaruzzi, C., Troncon, M. G., Agostinis, L., Wallander, M. A., and Johansson, S., “Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes”, Am J Epidemiol, vol. 150, pp. 476-81, 1999.
C. Seliger, Meier, C. R., Jick, S. S., Uhl, M., Bogdahn, U., Hau, P., and Leitzmann, M. F., “Use of cardiac glycosides and risk of glioma”, J Neurooncol, vol. 127, pp. 321-8, 2016.
L. Azoulay, Soldera, S., Yin, H., and Bouganim, N., “Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study”, Epidemiology, vol. 27, pp. 594-601, 2016.
F. de Vries, Souverein, P. C., Cooper, C., Leufkens, H. G., and van Staa, T. P., “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
R. G. Schlienger, Kraenzlin, M. E., Jick, S. S., and Meier, C. R., “Use of beta-blockers and risk of fractures”, Jama, vol. 292, pp. 1326-32, 2004.
L. Azoulay, Yin, H., Renoux, C., and Suissa, S., “The use of atypical antipsychotics and the risk of breast cancer”, Breast Cancer Res Treat, vol. 129, pp. 541-8, 2011.
J. Assayag, Pollak, M. N., and Azoulay, L., “The use of aspirin and the risk of mortality in patients with prostate cancer”, J Urol, vol. 193, pp. 1220-5, 2015.
C. Schneider, Adamcova, M., Jick, S. S., Schlagenhauf, P., Miller, M. K., Rhein, H. G., and Meier, C. R., “Use of anti-malarial drugs and the risk of developing eye disorders”, Travel Med Infect Dis, vol. 12, pp. 40-7, 2014.
C. Patch, Charlton, J., Roderick, P. J., and Gulliford, M. C., “Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study”, Am J Kidney Dis, vol. 57, pp. 856-62, 2011.
F. Andersohn, Schade, R., Willich, S. N., and Garbe, E., “Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior”, Neurology, vol. 75, pp. 335-40, 2010.
P. C. Souverein, Webb, D. J., Weil, J. G., van Staa, T. P., and Egberts, A. C., “Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy”, Neurology, vol. 66, pp. 1318-24, 2006.
[Page last reviewed 6 December 2019]